GlobalData on MSN

J&J’s nipocalimab meets primary endpoint in Phase II JASMINE study

The study is said to be the first to demonstrate efficacy for FcRn inhibition in SLE.

ATS 2026: DPP1 inhibitors reinforced with Phase II final pooled data from verducatib

The results provide validation of the DPP1 inhibition in bronchiectasis and reinforce the drug class’s position in this ...
Morningstar

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in ...

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical ...

MiNK outlines 90-patient randomized phase II ARDS trial with initial data expected in 2H 2026

Q1 2026 Management View Dr. Jennifer Buell (Co-Founder, President, CEO & Director) framed recent disclosures around clinical and mechanistic readouts across oncology and pulmonary indications, saying, ...
ascopubs.org

Dual targeting of VEGF and PD-1: A phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma.

Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
The Manila Times

ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader ...